pravastatin / Generic mfg. - LARVOL DELTA

Molecular MRI of Collagen Enables Evaluation of Fibrosis and Therapeutic Response in Venous Thrombosis. (PubMed, Circ Cardiovasc Imaging) - "A subgroup of mice with DVT (n=7) was treated with pravastatin in drinking water (40 mg/kg per d) for 3 weeks post-DVT...Statin treatment decreased both collagen accumulation and vein wall thickness, without affecting thrombus size. Molecular MRI using a collagen-targeting probe made collagenous thrombus visible on MRI and detected changes in collagen content during thrombus resolution."

Journal • Cardiovascular • Fibrosis • Hematological Disorders • Immunology • Thrombosis

Do the pharmacokinetics of statins explain psychiatric symptom improvement from adjunctive statin prescribing in severe mental illness? Three target trial emulation studies. (PubMed, BMJ Ment Health) - "There is currently not enough evidence to guide the prescription of statins for psychiatric symptom improvement in patients with SMI. If there is an effect of statins, it may be through specific statin-antipsychotic combinations."

Journal • PK/PD data • Bipolar Disorder • CNS Disorders • Mood Disorders • Psychiatry • Schizophrenia

Lipid-Lowering Therapy Is Underutilized Across LDL-C Levels in Autoimmune Disease Compared to Diabetes: A Nationwide Analysis (AHA 2025) - "Statins included atorvastatin, rosuvastatin, simvastatin, pravastatin, lovastatin, fluvastatin, pitavastatin. Non-statin therapies included icosapent ethyl, colesevelam, alirocumab, evolocumab, Bempedoic acid, cholestyramine, Inclisiran, colestipol, ezetimibe, gemfibrozil, omega-3 acid, fenofibrate...Non-statin lipid-lowering therapy use was significantly lower in autoimmune patients compared to those with diabetes across all LDL-C tertiles, with the largest differences observed at LDL <70 mg/dL (6.19% vs 10.24%, p<0.0001) and 70–99 mg/dL (4.05% vs 7.06%, p<0.0001).ConclusionDespite comparable ASCVD risk, patients with autoimmune disease are significantly less likely to receive statins or non-statin lipid-lowering therapy than those with DM across LDL-C levels. These findings show a need for improved cardiovascular prevention in this high-risk population."

Atherosclerosis • Cardiovascular • Diabetes • Dyslipidemia • Hepatology • Immunology • Inflammatory Arthritis • Lupus • Metabolic Disorders • Rheumatoid Arthritis • Rheumatology • Systemic Lupus Erythematosus

Targeting cancer stem-like cells via cholesterol modulation and ferroptosis induction using a multifunctional nanoplatform to overcome drug resistance. (PubMed, J Nanobiotechnology) - "Here, we develop Fe/CDP, a nanoparticle with a Fe3O4 core coated with chondroitin sulfate and loaded with pravastatin, a mevalonate pathway inhibitor, and doxorubicin (DOX). Moreover, cholesterol depletion facilitates lipid peroxidation, synergizing with Fe3O4 to trigger ferroptosis through CoQ10/GPX4/FSP1 downregulation. By eliminating both bulk tumor cells and CSCs, Fe/CDP provides a cholesterol-modulating strategy to overcome TNBC drug resistance."

Journal • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • AIFM2 • ALDH1A1 • EGFR • GPX4

Pravastatin and L-Arginine Use in Early-Onset Severely Growth-Restricted Dichorionic Twins: A Case Report. (PubMed, Am J Case Rep) - "This report supports findings from recent studies that combined pravastatin and L-arginine can improve fetal development and survival in FGR within monochorionic twin pregnancies. Adequately powered and randomized trials are needed to confirm this finding."

Journal • Gynecology

Impact of Obesity and MASH on Zonal Hepatocellular Statin Exposure: Pharmacodynamic Insights From a Permeability-Limited Multicompartment Liver Model. (PubMed, CPT Pharmacometrics Syst Pharmacol) - "Systemic and hepatocellular concentrations of pravastatin, rosuvastatin, and atorvastatin were simulated in Healthy Volunteers (HV), Obese, Morbidly Obese, and MASH virtual populations with the Simcyp Simulator. In MASH, unbound hepatocellular exposure increased by up to 127% in the periportal region for atorvastatin and decreased by up to 55% in the pericentral region for rosuvastatin. The pharmacodynamic model simulated decreased rosuvastatin cholesterol-lowering efficacy in MASH compared with Obese, which could be compensated for with a 50% increase in dose according to exploratory simulations."

Journal • PK/PD data • Dyslipidemia • Genetic Disorders • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Obesity

Pravastatin for the prevention of recurrent hypertensive disorders of pregnancy: study protocol for a randomized, open-label, parallel-group, three-arm trial. (PubMed, Trials) - "The results of this study are expected to have wide-ranging implications given the effects of hypertensive disorders of pregnancy on long-term maternal and child health, as well as health economics."

Journal • Cardiovascular • Critical care • Gynecology • Hematological Disorders • Hypertension • Renal Disease • Small for Gestational Age • Thrombocytopenia • FLT1

Statins Kill Acute Myeloid Leukemia Cells through Low-Density Lipoprotein Receptor-Mediated Unfolded Protein Response Activation (ASH 2024) - "However, the SWOG S0919 trial, which evaluated a combination of idarubicin, cytarabine, and pravastatin in relapsed/refractory AML cases, reported a high complete response (CR/CRi) rate of 75%...The cells were cultured in the presence of either 2µM atorvastatin, 2µM fluvastatin, or dimethyl sulfoxide (DMSO) as a control for 20 days...Furthermore, the identification of UPR stress as a major cause of AML cell death opens possibilities for developing novel molecular targeted therapies. In conclusion, our study revealed that statin-induced AML cell death is mediated by LDLR-induced UPR activation, providing new insights into potential therapeutic strategies for AML treatment."

Acute Myelogenous Leukemia • Dyslipidemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • Targeted Protein Degradation • ANXA5 • ATF4 • CASP3 • LDLR

Computational Evaluation of Statin Analogs Targeting HMG-CoA Reductase for Coronary Artery Disease Treatment. (PubMed, ChemistryOpen) - "ADMET analysis showed that analogs of simvastatin, lovastatin, and pravastatin have favorable pharmacological profiles and low toxicity...This ligand-induced rigidity is a powerful indicator of enhanced inhibitory efficacy and stability. Our findings highlight that statin analogs are a promising class whose unique binding dynamics offer a new, rational pathway for designing more effective HMG-CoA reductase inhibitors."

Journal • Cardiovascular • Coronary Artery Disease

Efficacy and safety of switching to ezetimibe 10 mg/rosuvastatin 2.5 mg in Korean patients with type 2 diabetes mellitus and dyslipidaemia: A multicentre, prospective study (EROICA study). (PubMed, Diabetes Obes Metab) - "Switching to ezetimibe 10 mg/rosuvastatin 2.5 mg achieved substantial LDL-C reductions, high goal attainment, excellent adherence, and good tolerability in Korean T2DM patients with dyslipidaemia."

Journal • Cardiovascular • Diabetes • Dyslipidemia • Metabolic Disorders • Type 2 Diabetes Mellitus • APOB

Immune checkpoint inhibition accelerates atherosclerosis via smooth muscle cell phenotypic modulation (AHA 2025) - "Importantly, both co-treatment with the HMGCR inhibitor pravastatin and SMC-specific deletion of Perk reversed nivolumab-induced SMC phenotypic modulation. Taken together, our data identify a novel effect of nivolumab on SMCs: activation of HSF1-HMGCR-PERK signaling, promoting pro-atherogenic phenotypic modulation. These results suggest that targeting cholesterol biosynthesis or PERK signaling may offer promising therapeutic strategies to prevent or treat ICI-induced atherosclerosis without compromising anti-tumor efficacy."

Checkpoint inhibition • IO biomarker • Atherosclerosis • Cardiovascular • Coronary Artery Disease • Oncology • HSF1 • PD-L1 • PD-L2

Successful Use of GLP-1 Receptor Agonist in Patient With Recurrent Hypertriglyceridemia-Induced Pancreatitis: A Case Report (ACG 2025) - "Her history included >25 hospitalizations for HTG-AP, with persistently elevated TG (up to 10,500 mg/dL) despite aggressive interventions, including maximum-dose lipid-lowering agents (gemfibrozil, orlistat, pravastatin), ileal bypass, and plasmapheresis. Two months prior, she started liraglutide therapy (0.6 mg/day), which significantly improved symptoms and prevented HTG-AP recurrence...Remarkably, the patient's most recent TG level of approximately 400 mg/dL represents the lowest value recorded in over a decade (Figure 1), indicating a clinically significant and sustained TG-lowering effect. This favorable response highlights the importance of individualized, patient-centered care and challenges conventional contraindications.Figure: Figure 1: Trend of serum triglyceride and lipase levels over time"

Case report • Clinical • Diabetes • Dyslipidemia • Genetic Disorders • Hypertriglyceridemia • Metabolic Disorders • Obesity • Pancreatitis • Type 2 Diabetes Mellitus • LPL

Drug-Induced Liver Injury With Combination Semaglutide and Atorvastatin (ACG 2025) - "Oral semaglutide 3mg was started for her diabetes and increased to 7mg a month later and changed from pravastatin 40mg to atorvastatin 20mg for persistent LDL elevation...Her home medications include levothyroxine, losartan, metformin, and a multivitamin...Although rare, with the increasing popularity of GLP-1 agonists and widespread use of statins, clinicians should be aware of this potential effect and monitor hepatic function when prescribing these medications in combination.Figure: Figure 1. Trends of liver enzyme elevation following initiation of semaglutide and atorvastatin with subsequent discontinuation of semaglutide."

Cardiovascular • Diabetes • Dyslipidemia • Endocrine Disorders • Genetic Disorders • Hepatology • Hypertension • Inflammation • Liver Failure • Metabolic Disorders • Obesity • Pancreatitis • Type 2 Diabetes Mellitus

Statin Use in Patients With Cancer: Drug Interaction and Statin Usage. (PubMed, JACC Adv) - "Statin-oncology agent DDIs are relatively common but rarely is statin use contraindicated. Frequency of statins use varies according to cancer type. These findings highlight the importance of individualized risk-benefit assessments that consider prognosis, cardiovascular risk, potential drug interactions, and patient preferences to guide statin use in cancer patients."

Journal • Breast Cancer • Cardiovascular • Dyslipidemia • Lung Cancer • Oncology • Solid Tumor

Comparative Effectiveness of Statins in Inflammatory Bowel Disease: A Propensity Score-Matched Real-World Study (ACG 2025) - "Introduction: While statins are known for their cardioprotective benefits, limited data exist comparing individual agents within the same intensity class in patients with Inflammatory Bowel Disease (IBD). Among high-intensity statins, rosuvastatin was associated with significantly lower all-cause mortality compared to atorvastatin in IBD (HR 0.73, p< 0.001), CD (HR 0.70, p< 0.001), and UC (HR 0.70, p< 0.001). Rosuvastatin also conferred greater reduction in CVD, CHD, and showed a non-significant trend toward lower PAD. Additionally, rosuvastatin was associated with a significantly lower risk of composite ASCVD outcomes in IBD (HR 0.65), CD (HR 0.61), and UC (HR 0.67), all p< 0.001."

Clinical • HEOR • Real-world • Real-world evidence • Atherosclerosis • Cardiovascular • CNS Disorders • Coronary Artery Disease • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Heart Failure • Immunology • Inflammation • Inflammatory Bowel Disease • Peripheral Arterial Disease • Ulcerative Colitis • Vascular Neurology

Effect of Statin Intensity on Tolerability, Lipid Levels, and Cardiac Function After Transplantation. (PubMed, ASAIO J) - "Standard intensity statin was defined as pravastatin ≤20 mg or equivalent doses, while higher doses were defined as intensified statin...Left ventricular global longitudinal strain (n = 53) from 1 to 3 years after HT was lower by -10% in those on standard compared with -2% on intensified statin (p = 0.03). In conclusion, intensified statin is well tolerated after HT, leads to better LDL control, and is associated with greater preservation of myocardial function."

Journal • Dyslipidemia • Transplantation

AN ATYPICAL CASE OF HEMOPTYSIS DUE TO BRONCHIAL PETECHIAE FROM ESCITALOPRAM USE (CHEST 2025) - "Outpatient medications include amlodipine, losartan, levothyroxine, furosemide, omeprazole, pravastatin, sodium bicarbonate, sevelamer carbonate, and escitalopram...The patient was initiated on empiric ceftriaxone and doxycycline...The patient's hemoptysis had resolved at this time and was discharged with Amoxicillin/ Clavulanate for a total course of seven days... When evaluating patients with hemoptysis with diffuse bronchial petechiae, it is imperative to consider potential offending medications through comprehensive medication reconciliation if no clear causative etiology is identified. SSRIs have common side effects such as gastrointestinal symptoms, weight changes, anticholinergic symptoms, hyponatremia, QT prolongation and possibly serotonin syndrome. Due to the SSRIs role in platelet serotonin depletion, they may be implicated in bleeding events."

Clinical • Cardiovascular • Chronic Kidney Disease • Dyslipidemia • Endocrine Disorders • Heart Failure • Hematological Disorders • Hypertension • Immunology • Infectious Disease • Nephrology • Otorhinolaryngology • Pneumonia • Pulmonary Disease • Renal Disease • Respiratory Diseases • Thrombocytopenia

ANAPHYLAXIS AND PEA ARREST FOLLOWING ADMINISTRATION OF SULFUR HEXAFLUORIDE INTRAVENOUS CONTRAST (CHEST 2025) - "Allergies were Pravastatin and Penicillin only...After ROSC was achieved, methylprednisolone and diphenhydramine were given. Soon after, the patient had another episode of PEA arrest which required two rounds of CPR and Epinephrine to achieve ROSC. The patient was started on Dobutamine and transferred to Intensive Care...The patient's home Warfarin was resumed for anticoagulation and then she was discharged home... To our knowledge, our case is the first reported to have two episodes of PEA cardiac arrest accompanying anaphylactic shock after Lumason contrast administration. Clinicians should be aware of this rare but life-threatening reaction, and if a known allergy to PEG exists to avoid the procedure."

Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Diabetes • Genetic Disorders • Heart Failure • Hypotension • Immunology • Metabolic Disorders • Obesity • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Disorder • Thrombosis • Type 2 Diabetes Mellitus

Development and Application of an Algorithm for Statin-Induced Myopathy Based on Electronic Health Record-Derived Structured Elements. (PubMed, Pharmacoepidemiol Drug Saf) - "We have produced an efficient, easy-to-apply methodological tool that can improve the quality of future research on SIM."

Journal • Endocrine Disorders • Myositis

In immune-mediated necrotising myopathy, anti-HMGCR antibodies inhibit HMGCR activity, leading to the sarcoplasmic accumulation of lipid droplets and myofibres necrosis (ACR Convergence 2025) - "Pravastatin was used as a negative control... Together, these data demonstrate that anti-HMGCR antibodies inhibit HMGCR activity, leading to the sarcoplasmic accumulation of lipid droplets and myofibres necrosis. These findings could have implications for both the diagnosis and treatment of IMNM."

CNS Disorders • Myositis

TRADstat: Novel Treatment of Radiation Associated Dysphagia With Statins (clinicaltrials.gov) - P2 | N=48 | Not yet recruiting | Sponsor: Peter MacCallum Cancer Centre, Australia

New P2 trial • Gastrointestinal Disorder • Head and Neck Cancer • Oncology • Solid Tumor

Cell membrane-based nanovesicles as potential drug delivery systems for atherosclerosis therapy. (PubMed, Colloids Surf B Biointerfaces) - "In this study, we present the development, characterization and therapeutic activity of pravastatin-loaded nanovesicles (PRA-loaded NVs) derived from RAW 264.7 macrophage cell membranes...Functional assays also confirmed the preservation of PRA therapeutic effect by reducing pro-inflammatory cytokines and promoting cholesterol release from foam cells. Hence, these findings highlight the potential of biomimetic NVs as innovative therapeutic agents for atherosclerosis treatment."

Journal • Atherosclerosis • Cardiovascular • Myositis • ITGA4 • ITGAM

Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose) (clinicaltrials.gov) - P2 | N=250 | Recruiting | Sponsor: M.D. Anderson Cancer Center | Not yet recruiting ➔ Recruiting

Enrollment open • Fibrosis • Head and Neck Cancer • Immunology • Oncology • Solid Tumor

A randomized controlled trial evaluated the effect of pravastatin on kidney disease outcomes in adult patients with early-stage autosomal dominant polycystic kidney disease. (PubMed, Kidney Int) - "Among adult patients with ADPKD and preserved kidney function, pravastatin did not slow the increase in HtTKV and had no effect on slowing the decline in kidney blood flow and kidney function compared to placebo."

Journal • Autosomal Dominant Polycystic Kidney Disease • Genetic Disorders • Nephrology • Polycystic Kidney Disease • Renal Disease

Systematic Review of the Management of Fibrosis in Head and Neck Cancer Patients (AAO-HNSF 2025) - "Among the eight studies analyzed, pharmacological interventions included pentoxifylline-tocopherol, pravastatin, amifostine, and topical superoxide dismutase (SOD). Improvements in HNC fibrosis after current treatments range from 35% to 97% of patients, with combination therapies offering the most promising results. Further research is needed to investigate and optimize long-term outcomes of these therapies."

Clinical • Review • Fibrosis • Gastrointestinal Disorder • Head and Neck Cancer • Immunology • Oncology • Solid Tumor